|
Novartis gains FDA approval for Gilenya(TM), a novel first-line multiple sclerosis treatment
|
23 September 2010 |
|
Novartis JAK inhibitor provides marked and durable clinical benefits in patients with myelofibrosis
|
16 September 2010 |
|
Meningococcal B vaccine candidate could be first to provide broad coverage against deadly disease
|
13 September 2010 |
|
Novartis and collaborators discover novel antimalarial drug candidate
|
06 September 2010 |
|
Novartis awards 2010 Prizes for Immunology in recognition of outstanding contributions to immunology in medical research
|
25 August 2010 |
|
Sandoz leads the way with first generic version of 'gold standard' anti-thrombotic Lovenox®
|
26 July 2010 |
|
Novartis delivers strong financial performance in second quarter
|
20 July 2010 |
|
Phase III study shows Novartis drug Afinitor® more than doubles time without tumor growth
|
02 July 2010 |
|
FDA approves Tasigna® for newly diagnosed chronic myeloid leukemia patients
|
22 June 2010 |
|
FDA advisory committee recommends approval of Novartis investigational treatment FTY720
|
14 June 2010 |